We studied the presynaptic muscarinic autoreceptor subtypes controlling ACh release and their relationship with voltage-dependent calcium channels in the neuromuscular synapses of the Levator auris longus muscle from adult (30-40 days) and newborn (3-6 and 15 days postnatal) rats. Using intracellular recording, we studied how several muscarinic antagonists affected the evoked endplate potentials. In some experiments we previously incubated the muscle with calcium channel blockers (nitrendipine, o-conotoxin-GVIA and o-Agatoxin-IVA) before determining the muscarinic response. In the adult, the M1 receptor-selective antagonist pirenzepine (10 mM) reduced evoked neurotransmission (% 47%). The M2 receptor-selective antagonist methoctramine (1 mM) increased the evoked release (% 67%). Both M1-and M2-mediated mechanisms depend on calcium influx via P/Q-type synaptic channels. We found nothing to indicate the presence of M3 (4-DAMP-sensitive) or M4 (tropicamide-sensitive) receptors in the muscles of adult or newborn rats. In the 3-6-day newborn rats, pirenzepine reduced the evoked release (% 30%) by a mechanism independent of L-, N-and P/Q-type calcium channels, and the M2 antagonist methoctramine (1 mM) unexpectedly decreased the evoked release (% 40%). This methoctramine effect was a P/Q-type calcium-channel-dependent mechanism. However, upon maturation in the first two postnatal weeks, the M2 pathway shifted to perform the calcium-dependent release-inhibitory activity found in the adult. We show that the way in which M1 and M2 muscarinic receptors modulate neurotransmission can differ between the developing and adult rat neuromuscular synapse.
Introduction
Presynaptic muscarinic autoreceptors are involved in the modulation of neurotransmitter release and synaptic efficacy in cholinergic synapses (see Caulfield, 1993 for a review). Both enhancement and reduction in release coupled to muscarinic mechanisms have been described (Ganguly & Das, 1979; Abbs & Joseph, 1981; Wessler et al., 1987; Arenson, 1989) . Five muscarinic receptor (mAChRs) subtypes (M1-5) have been described and their genes have been cloned and expressed. However, the type(s) related to the inhibition or enhancement of acetylcholine release in the various central and peripheral cholinergic circuits are not fully resolved (Slutsky et al., 1999; Allen, 1999; Arellano et al., 1999; Minic et al., 2002) . The enhancement of ACh release has been related to the M1 receptor in peripheral vagal nerve endings (Ren & Harty, 1994) . In the inhibition of release, it seems that M2 receptors are mainly involved in basal forebrain neurons Allen, 1999) , although M3 receptors in neostriatum (Hsu et al., 1995) and indeed the M1 receptor in cerebral cortex and hippocampus also seem to be involved (Vannucchi & Pepeu, 1995) . It has recently been shown that, in the neuromuscular junctions of the frog (Slutsky et al., 1999) and mouse (Minic et al., 2002) , presynaptic M1 and M2 subtypes of mAChRs are involved in the feedback modulation of the ACh release. The M1 type enhances release whereas the M2 type inhibits it. Normally, endogenous ACh concentration in the synaptic cleft is enough to activate both processes and the net effect is a tonic inhibition of release (Slutsky et al., 1999) .
There is some evidence for the ionic basis underlying mAChRmediated release modulation. M1 and M3 receptors preferentially couple to pertussis toxin (PTX)-insensitive G-proteins of the Gq/1l family to stimulate phospholipase C, while M2 and M4 receptor activation couples to PTX-sensitive G-proteins of the Gi/Go family to inhibit adenylyl cyclase (Caulfield, 1993; Felder, 1995; Caulfield & Birdsall, 1998 ; but see Nathanson, 2000) . Both intracellular pathways can modulate voltage-dependent calcium channels (VDCC). It seems that M1-mediated ACh release enhancement was associated with an increase in Ca 2þ current in the neuromuscular junction (NMJ) of the frog (Slutsky et al., 1999) . Observations of several central and peripheral synapses suggest that a reduction in Ca 2þ influx underlies the muscarinic-mediated inhibition of release (Wanke et al., 1987; Wessler et al., 1987; Hamilton & Smith, 1991; Allen, 1999) . However, release inhibition seems sometimes not to depend on the concentration of external calcium (Muller et al., 1987; Dolezal & Túcek, 1993) or not to be associated with a reduction in presynaptic Ca 2þ currents (Slutsky et al., 1999) .
In this study we investigated the presence of different subtypes, the functional behaviour and the VDCC-dependence of the mAChRs in the motor nerve terminals of the Levator auris longus (LAL) muscle from the newborn to the adult rat.
Materials and methods

Animals
Experiments were performed on theLAL muscle of adult (30-40 days) and neonatal (3-15 days) Sprague-Dawley rats (Criffa, Barcelona, Spain). The rats were cared for in accordance with the guidelines in the European Community's Council Directive of 24 November 1986 (86/ 609/EEC) for the humane treatment of laboratory animals. The rats were anaesthetized with 2% tribromoethanol (0.15 mL/10 g body weight, i.p.)
Electrophysiological recordings
The muscle, with its nerve supply, was excised and dissected on a Sylgard-coated Petri dish containing normal Ringer solution (in mM): NaCl, 137; KCl, 5; CaCl 2 , 2; MgSO 4 , 1; NaHCO 3 , 12; Na 2 HPO 4 , 1; and glucose, 11; continuously bubbled with 95% O 2 /5% CO 2 . The preparation was then transferred to a recording chamber of 5 mL for adult muscles and 1 mL for neonatal LAL muscles. The bathing solution was circulated at 8 mL/h with a peristaltic pump Gilson) . Experiments were performed at room temperature (22-25 8C). The bathing temperature was also monitored during experiments (23.4 8C AE 1.7; Digital Thermometer TMP 812, Letica, Barcelona, Spain).
Evoked endplate potentials (EPPs) were recorded intracellularly with conventional glass microelectrodes filled with 3M KCl (resistance: 20-40 MO for adult rats and 40-70 MO for newborn rats).
Recording electrodes were connected to an amplifier (Tektronics, AMS02), and a distant Ag-AgCl electrode connected to the bath solution via an agar bridge (agar 3.5% in 137 mM NaCl) was used as reference. The signals were digitized (DIGIDATA 1200 Interface, Axon Instruments Inc, CA, USA), stored and analysed by computer. We used Axoscope 8.0 software (Axon Instruments) to acquire and analyse data.
We analysed dose-response relationships of muscarinic antagonists on miniature endplate potentials (MEPPs) from adult muscles. Our most important consideration was to discard the postsynaptic effects of the drugs and so choose the highest drug concentration that did not change the size of the MEPPs. We recorded MEPPs intracellularly and calculated and corrected the mean amplitude per fibre by assuming a membrane potential of À80 mV. We concluded that the highest concentrations of pirenzepine, methoctramine and 4-DAMP can affect the nicotinic postsynaptic receptors and reduce the size of MEPPs (amplitude reduction 31.40 AE 0.42, 47.82 AE 13.00 and 36.90 AE 0.96% for pirenzepine 100 mM, methoctramine 10 mM and 4-DAMP 10 mM, respectively; in all cases P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle).
To prevent stimulation-induced contractions, the muscles were cut on either side of the main intramuscular nerve branch (Hubbard & Wilson, 1973) . We performed a preincubation with normal Ringer for 30 min after cutting the muscles and before doing the experiment. In this study we did not use d-tubocurarine to prevent stimulationinduced contractions because it had already modified the action of muscarinic drugs in a preliminary set of experiments (data not shown). Moreover, the cut-fibre muscle preparations became partially depolarized, which inactivated voltage-dependent sodium channels (mean membrane potential for the adult cut fibre preparations after 30 min of muscle cut, 43.53 AE 0.77 mV, n ¼ 25 muscles; this membrane potential did not change significantly during long exposures to the muscarinic antagonists). Muscle contractions were almost eliminated therefore but the possible dependence of the presynaptic muscarinic mechanisms on calcium inflow was preserved. We also cut the muscles of the neonatal rats to prevent stimulation-induced contractions. With this procedure we saw small EPPs without the attenuating effect of curare or low extracellular calcium.
After a muscle fibre had been impaled, the nerve was continuously stimulated (70 stimuli for adult rats and 20 stimuli for newborn rats, both at 0.5 Hz) using two platinum electrodes coupled to a pulse generator associated to a stimulus isolation unit. We recorded the last 50 EPPs for the adult rats and the last 10 EPPs for the newborn rats. In the population studies, the EPP amplitudes before (control) and after 1 h incubation with drugs or toxins were recorded from a minimum of 15 fibres per muscle in adult and in newborn muscles. In the singlefibre experiments (the time course for the effect of the drugs on the EPPs of the same permanently impaled fibre), the drug or toxin was added to the bathing solution and the EPPs were recorded every 15 min for 60-120 min. The intensity of the stimulus was always 3Â the threshold.
In the adult experiments, records were rejected if the membrane potential (Vm) was <À30 mV or if this fell by >5 mV during the recording period. The mean amplitude (mV) per fibre was calculated and corrected for nonlinear summation (EPPs were usually >4 mV; McLachlan & Martin, 1981 ) assuming a membrane potential of À80 mV. In the neonatal animal, the mean amplitude (mV) per fibre was calculated and corrected assuming a membrane potential of À35 mV (mean membrane potential of LAL 3-to 6-day-old muscle fibres after 30 min of muscle cut was À35.72 AE 1.77 mV, n ¼ 24 muscles).
The records were rejected if the rise time was >1 ms for the adult rats. In the experiments on newborn rats, we recorded from sites where the EPP had the steepest rise time possible (usually <5 ms) to ensure that the recordings were made close to the endplate(s).
Statistical procedure
Values are expressed as means AE SEM. We used a one-way analysis of variance (ANOVA) to evaluate differences between groups and the Bonferroni test to make multiple comparisons. When evaluating differences between only two groups, we used two-tailed Welch's ttest (for unpaired values and not assuming equal variances). Differences were considered significant at P < 0.05.
Chemicals
Muscarinic agents
Stock solutions: pirenzepine dihydrochloride, 10 mM (Tocris); methoctramine tetrahydrochloride, 1 mM (Sigma); N-ethyl-3-hydroxy-2-phenyl-N-(pyridinylmethyl)propanamide (tropicamide; Tocris), 10 mM in dimethylsulfoxide (DMSO); 1,1-dimethyl-4-diphenylacetoxy-piperidinium iodide (4-DAMP), 100 mM (Tocris); muscarine chloride, 5 mM (Sigma);oxotremorinesesquifumarate(oxotremorine-T),1 mM(Sigma); AF-DX 116 (Tocris), 100 mM in DMSO. Working solutions: pirenzepine, 10 mM; methoctramine, 1 mM; tropicamide, 1 mM; 4-DAMP, 1 mM; muscarine, 50 mM; oxotremorine T, 1 mM; and AF-DX 116, 10 mM. All stock solutions were stored at 4 8C for <4 weeks.
Calcium channel blockers
Nitrendipine (Research Biochemicals Inc.) was made up as a 50-mM stock solution in DMSO, stored at 4 8C and protected from light. Experiments in the presence of nitrendipine were carried out in the absence of direct illumination. The toxins o-conotoxin GVIA (o-CgTX-GVIA) and o-Agatoxin IVA (o-Aga-IVA) were purchased from Research Biochemicals Inc. Controls and toxin-treated muscles were assayed in the presence of 0.01% BSA (Sigma, St. Louis, MO, USA). Working solutions: nitrendipine, 1 mM; o-Aga-IVA, 100 nM; o-CgTX-GVIA, 1 mM. The final DMSO concentration in control and drug-treated preparations (nitrendipine, tropicamide and AF-DX 116) was 0.1% (v/v). In control experiments this concentration of DMSO did not affect any of the parameters studied (data not shown).
Results
Changes in evoked ACh release in the adult LAL muscle Figure 1A shows the mean amplitude of the EPPs recorded before (control) and after (1 h) incubation with four selective muscarinic antagonists, expressed as the percentage of change. Methoctramine (1 mM; a selective antagonist for the M2 receptor) significantly increased the EPP amplitude (% 67%; P < 0.05; n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 1A ). Pirenzepine (10 mM; a selective antagonist for the M1 receptor) significantly reduced the EPP amplitude (% 47%; P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 1A ).
We also tested how methoctramine and pirenzepine affected EPP amplitude in single adult fibres that were continuously monitored for at least the first 60 min after the drugs were added to the bath (Fig. 1B) . The time course of pirenzepine action was similar (although in the opposite direction) to that of the methoctramine-induced increase in release as shown in Fig. 1B . These results show that in the adult NMJs M1 receptors can enhance release and M2 receptors can reduce release when operated by endogenous ACh. The nonselective agonists muscarine (50 mM) and oxotremorine T (1 mM) did not modify transmitter release in the NMJs of the LAL muscle (% 8 and %14% change, respectively; P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle in both cases). We think that nonselective global muscarinic activation produces the action of functionally opposed M1-and M2-receptor subtypes, and results in the observed lack of effect of muscarine and oxotremorine T.
Interestingly, the muscarinic antagonists pirenzepine and methoctramine affected neurotransmitter release in almost exactly opposite ways ( Fig. 1A and B). We also found that, when both drugs were sequentially added to the muscle preparation, their effects completely cancelled each other out. After a first incubation with pirenzepine (10 mM), which reduced the EPP amplitude (inhibition 54.30 AE 4.60%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle), a second incubation with methoctramine (1 mM) restored the initial control value of EPP amplitude (recovery: 97.30 AE 5.35%, P > 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). This clearly shows that a dual M1-M2 mAChR-operated mechanism modulates transmitter release in adult rat NMJs.
In the adult LAL muscle, we found no evidence of M3 or M4 muscarinic receptors because EPP amplitude was unaffected by 4-DAMP (1 mM) and tropicamide (1 mM; a potent M4 antagonist, Caulfield & Birdsall, 1998; Arellano et al., 1999) , respectively (change %5 and %10%, respectively; in both cases, P > 0.05; Fig. 1A ).
Additionally, we performed several associations of drugs to further differentiate between M1, M2, M3 and M4 muscarinic receptors. After a preincubation with pirenzepine (10 mM) or methoctramine (1 mM), tropicamide was still unable to produce significant changes in EPPs (change %15 and %3%, respectively; in both cases, P > 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). Also, a previous incubation with tropicamide did not further modify the described effect on EPP size induced by pirenzepine (diminution %44%, P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle) or methoctramine (increase %73%, P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). All these data reinforce the suggestion that M4 is not functionally present in NMJs and indicate the highly selective effect of the pirenzepine and methoctramine on the M1 and M2 receptors, respectively.
We also performed associations of 4-DAMP with the other drugs [4-DAMP and one of the other drugs (tropicamide, pirenzepine or methoctramine) were sequentially added in any order]. After a preincubation with pirenzepine (10 mM), methoctramine (1 mM) or tropicamide (1 mM), the addition of 4-DAMP was unable to produce significant changes in EPPs (change %2, %8 and %7%, respectively; in all cases, P > 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). Also, a previous incubation with 4-DAMP did not further modify the described effect on EPP size induced by pirenzepine (diminution %50%, P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle) or methoctramine (increase %83%, P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle), nor did it modify the lack of effect of tropicamide FIG. 2 . Effect of M1 and M2 receptor antagonists on adult EPPs when the P-type calcium channels are blocked. Values are expressed as percentage (mean AE SEM) of initial mean amplitude. (A) First column, methoctramine (1 mM) effect in adult NMJ; second column, methoctramine effect on EPPs amplitude in presence of oAga-IVA (100 nM); third column, the same kinds of experiments as in the second column were performed in high calcium (5 mM) medium; fourth column, the same kinds of experiments as in the second column were performed in high calcium and then washed out (100 mL, 1 h) with a normal Ringer solution containing methoctramine and o-Aga-IVA (high calcium was washed out). (B) First column, pirenzepine (10 mM) effect in adult EPPs; second column, pirenzepine effect on EPPs amplitude in presence of o-Aga-IVA (100 nM); third column, the same kinds of experiment as in the second column were performed in high calcium (5 mM). (C) Examples of time course effect of methoctramine (1 mM; left) and pirenzepine (10 mM; right) on EPPs recorded from the same junctions performed in normal Ringer ( ) and high calcium (5 mM; &). These experiments were performed in the presence of o-Aga-IVA (100 nM). The EPPs recorded in the high calcium medium usually are of higher amplitude than in normal Ringer experiments. To plot in the same ordinate scale, we have used the percentages of initial EPP values. (D) Example of time course effect of methoctramine in high calcium and o-Aga-IVA presence and when high calcium is removed. After 1 h of o-Aga-IVA incubation in the presence of high calcium (5 mM), EPPs were recorded every 15 min for 135 min from the same muscle fibre. The first recording was made 70 min after the onset of o-Aga-IVA and high calcium incubation (the o-Aga-IVA-induced effect reached a steady state) and 15 min before methoctramine (1 mM) was added to the bath. An EPP was immediately recorded and the records were then made every 15 min for 1 h (four times). After that, the normal ringer was circulated at 1.7 mL/min (high calcium was removed) and the EPPs were also recorded every 15 mins for 1 h (four times). With o-Aga-IVA preincubation in the presence of high Ca 2þ (5 mM) the effect of methoctramine was unaltered but this could not be maintained when we returned to normal calcium. For each column n ¼ 5 muscles, minimum 15 fibres by muscle.
(change %12%, P > 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). All these data reinforce the suggestion that M3 is not functionally present in NMJs.
In summary, M1 and M2 mAChRs seem to modulate transmitter release in the LAL muscle of adult rats.
Role of calcium channels on the mAChR modulation of ACh release in the adult LAL muscle NMJ In mature mammalian motoneurons, neuromuscular transmission depends strongly on the influx of calcium from the external media via presynaptic voltage-dependent calcium channels (VDCC; Katz & Miledi, 1970) especially the P/Q-type (Uchitel et al., 1992; Protti & Uchitel, 1993; Bowersox et al., 1995; Hong & Chang, 1995) . In the adult LAL endplates, the P/Q-type channel blocker o-Aga-IVA (100 nM) significantly reduced the EPP amplitude (% 75%, P < 0.05) whereas o-CgTX-GVIA did not significantly reduce the transmitter release. Previously incubating with o-Aga-IVA affected the transmitter-release action of the muscarinic blockers methoctramine and pirenzepine. This completely occluded both the ACh release-enhancement effect of the M2 blocker methoctramine (change 4.23 AE 2.40%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 2A ) and the release-inhibitory effect of the M1 blocker pirenzepine (change 3.21 AE 1.30%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 2B ). Therefore, both M1-and M2-mediated mechanisms of transmitter-release modulation seem to completely depend on the calcium influx via the P/Q-type synaptic channel. However, we found a substantial difference between the M1 and M2 mechanisms. When these experiments were performed with o-Aga-IVA preincubation in the presence of high Ca 2þ (5 mM), pirenzepine had no effect (3.07 AE 1.70%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 2B ), whereas the effect of methoctramine was unaltered (release enhancement 72.59 AE 7.30%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 2B ; see also Fig. 2C and D) . In summary, the M1-mediated pirenzepine effect may be related to the P/Q-type channel whereas the M2 mechanism seems to be related only to the amount of calcium entry.
To be sure of the effect of o-Aga-IVA in the presence of high Ca 2þ , we performed several controls. In the presence of 5 mM Ca 2þ , the mean EPP amplitude was higher than in normal Ringer (enhancement 124.90 AE 3.11%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). However, o-Aga-IVA can inhibit the size of EPPs in 5 mM Ca 2þ (66.72 AE 3.38%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle) as in normal Ringer (75.03 AE 7.15%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). Therefore, the P/Q-type channel was effectively blocked in the experiments with high calcium. However, when the high Ca 2þ was added to a preparation blocked with o-Aga-IVA, release was enhanced (201.01 AE 34.01%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). This shows that external calcium can flow in despite the P/Q-type channel block, and suggests that the M2 mechanism actually depends only on the availability of sufficient internal calcium, not on the VDCCs involved in conducting the inflow.
Changes in evoked ACh release in the newborn LAL muscle
We studied how the muscarinic autoreceptors are involved in evoked neurotransmitter release in the NMJs of newborn (3-6 days postnatal) animals by using the blockers methoctramine, pirenzepine, 4-DAMP and tropicamide (Fig. 3A) . We grouped the data from all 4 days together because there were no differences for any of the parameters, even at between 3 and 6 days (P > 0.05). As expected for this postnatal period, all EPPs had a smaller quantal content and longer latency, and were relatively slower in their rise-time rate than those found elsewhere in mature muscles (P < 0.05 in all cases; see Santafé et al., 2001) . As in the adult rats, we found a pirenzepine-induced EPP reduction (% 30%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 3A) . Therefore, a pirenzepine-sensitive M1-operated release-enhancement mechanism seemed to be acting in the newborn endplates. However, we found that the M2 antagonist methoctramine (1 mM) unexpectedly decreased the amplitude of the evoked EPPs (% 40%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 3A ), which is in opposition to their previously described action in adults. This differential effect in newborn and adult NMJs was reproduced by the selective M2 antagonist AF-DX 116 (10 mM; newborn EPP amplitude reduction 43.97 AE 4.31%, adult EPP amplitude potentiation 44.08 AE 2.99%; in both cases, P < 0.05, n ¼ 3 muscles, minimum 15 fibres per muscle). When methoctramine and pirenzepine were sequentially added (in whatever order), the ACh release reduction produced by the first drug was not increased (or reversed) by the second drug. For instance, after a first EPP amplitude reduction by methoctramine (59.20% AE 7.70, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle), incubating with pirenzepine did not further affect the size of the EPPs (change 6.16 AE 3.20%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). However, the adult profile of the action of methoctramine on M2 receptors was observed at 2 weeks postnatal (methoctramine-induced EPP potentiation in 15-day-old-rats %70%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; methoctramine values in 15-day-old rats were not significantly different from the values for adult rats, P > 0.05; Fig. 3B ). Figure 3C shows the experiments for determining the effects of pirenzepine and methoctramine on EPP amplitude in single newborn fibres that were continuously monitored for at least the first 60 min after the drugs were added to the bath.
As in adult rats, M3 antagonist 4-DAMP (1 mM) and M4 antagonist tropicamide (1 mM) did not modify the EPP amplitude (change %8 and %6%, respectively; in both cases, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 3A) .
Role of calcium channels in the mAChR modulation of ACh release in the LAL muscle NMJs of newborn rats
We first studied how specific P/Q-, L-and N-type calcium-channel blockers affect supramaximal EPP amplitude in the NMJs of newborn rat LAL muscle. The L-type channel blocker nitrendipine (10 mM) did not significantly change the EPP amplitude (change 30.38 AE 31.03%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). However, the P/Q-type channel blocker o-Aga-IVA (100 nM) and the N-type channel blocker o-CgTX-GVIA (1 mM) did reduce the EPP amplitude (blockade 67.65 AE 7.11 and 49.76 AE 8.24%, respectively; in both cases, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle). These results are close to those of other studies (see Rosato-Siri & Uchitel, 1999) carried out in similar conditions.
We therefore investigated how the L-, P/Q-and N-type VDCCs are involved in the muscarinic mechanisms acting in the whole postnatal NMJ (Fig. 4) . As expected, the L-type VDCC blocker Nitrendipine did not modify the pirenzepine and methoctramine effects on EPPs. The blocking of the P/Q-type channel by previous o-Aga-IVA incubation did not prevent the pirenzepine from affecting EPP size (inhibition %40%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 4A) . Also, the pirenzepine-induced release inhibition was not FIG. 4 . Effect of pirenzepine and methoctramine on EPPs of newborn rats when the L-, N-or P-type calcium channels are blocked. Columns are the percentage (mean AE SEM) of initial mean amplitude. (A) First column, pirenzepine (10 mM) effect on EPPs of newborn rats; second column, pirenzepine effect on EPP amplitude in presence of nitrendipine (1 mM); third column, pirenzepine effect on EPP amplitude in presence of o-CgTX-GVIA (1 mM); fourth column, pirenzepine effect on EPP amplitude in presence of oAga-IVA (100 nM). Note that neither VDCC calcium channel seems to be involved in the pirenzepine action. (B) First column, methoctramine (1 mM) effect on EPPs of newborn rats; second column, methoctramine effect on EPP amplitude in presence of nitrendipine (1 mM); third column, methoctramine effect on EPP amplitude in the presence of o-CgTX-GVIA (1 mM); fourth column, methoctramine effect on EPP amplitude in presence of o-Aga-IVA (100 nM), fifth column, the same experiments as those in the fourth column were performed in high calcium (5 mM) medium. For each column n ¼ 5 muscles, minimum 15 fibres by muscle. (5 mM), pirenzepine reduced the EPP amplitude (see an example in Fig. 5 ). Unlike in adult rats, therefore, the M1-mediated pirenzepinesensitive mechanism in young rats did not involve VDCC.
On the other hand, previous incubation with o-CgTX-GVIA did not modify the methoctramine effect (release inhibition %50%, P < 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 4B ). Previous incubation with o-Aga-IVA, however, prevented the M2 blocker methoctramine from decreasing the EPP size (change <2%, P > 0.05, n ¼ 5 muscles, minimum 15 fibres per muscle; Fig. 4B ). When we performed these experiments in the presence of high Ca 2þ (5 mM), methoctramine could not modify the EPP amplitude in o-Aga-IVA-preincubated muscles (change %5%, P > 0.05) but it reduced the EPP amplitude in o-CgTX-VIA-preincubated muscles ( Fig. 4B ; see examples in Fig. 5 ). Therefore, in newborn rats P/Q channels were involved in the effect of methoctramine.
In summary, in the newborn rat there is an M1-mediated, pirenzepine-sensitive and VDCC-independent release-enhancing mechanism that upon maturation can acquire P/Q-type VDCC dependence in the adult. There is also an M2-mediated methoctramine-sensitive and VDCC-dependent (P/Q-type) mechanism that operates to enhance transmitter release. However, upon maturation in the first few weeks postnatal, the M2 pathway shifts to perform a calcium-dependent release-inhibitory activity.
Discussion mAChRs in the adult rat LAL muscle
In adult rats, we found evidence for mechanisms of M1-receptormediated ACh release enhancement and M2-receptor-mediated release inhibition.
That there is more than one receptor type to explain the muscarinic inhibition of ACh release was suggested several years ago (M2 and M3, Ren & Harty, 1994; M2 and M1, Vannucchi & Pepeu, 1995) . However, the dual M1-M2 (enhancement-inhibition) pattern of mAChRs has only recently been found in frog NMJs using focal depolarization of the presynaptic terminal (Slutsky et al., 1999) and in mice (Minic et al., 2002) .
We need to determine what role these opposite muscarinic-mediated mechanisms of ACh release modulation have in the living animal. We also need to determine which synaptic activity conditions enhance release and which conditions inhibit it. It has recently been found in the preparation of mouse phrenic hemidiaphragm that, in several conditions in which acetylcholinesterase is inactive, the predominant effect of mAChRs may be to enhance ACh release by the M1 receptor subtype (Minic et al., 2002) . In our study, we reproduced a physiological activation of the NMJs with (i) action potentials arriving at the nerve terminal, (ii) normal extracellular calcium, (iii) unblocked postsynaptic receptors and (iv) normal physiological activity of acetylcholinesterase. In these conditions, as we have already mentioned, M1 and M2 mechanisms can operate in parallel and balance each other out. To study EPP size (mV), we used a low frequency of activation (0.5 Hz). The change in the resting ACh concentration in the synaptic cleft (which is considered to be between 10 À8 and 10 À9 M; Katz & Miledi, 1977; Slutsky et al., 1999) may be different from the phasic oscillations that are assumed to occur in the living animal after a burst of high frequency (% 80 Hz). Perhaps differences between M1 and M2 activation occur at higher levels of ACh release. A precise determination of the M1 and M2 conditions of physiological function may therefore require additional work with different physiological stimulation patterns. We performed preliminary experiments to study how methoctramine and pirenzepine affect the size of EPPs in trains at 10 Hz and found no difference between the size of EPPs at this frequency and those at 0.5 Hz.
Transmitter release can be self-modulated by autoreceptors on the presynaptic terminal itself (see Starke et al., 1989 , for a review). Levey, 1997). To date, direct evidence of mAChRs in newborn and adult skeletal muscle fibres is partial. Recently, M1 mAChRs have been observed in mice NMJs (Minic et al., 2002) . We observed M1 and M2 receptors by immunocytochemistry in both newborn and adult neuromuscular junctions, although a clear and direct demonstration at the presynaptic NMJ is lacking (M.M. Santafé, I. Salon, N. Garcia, M.A. Lanuza, O.D. Uchitel & J. Tomàs, unpublished results) . Therefore, we cannot completely rule out the involvement of the muscle and/ or teloglial cells in the effects of the muscarinic agents. However, we found that, at the concentrations used, the drugs did not modify the single quantum event and that a postsynaptic effect is therefore unlikely. The P/Q-type (the presynaptic one in the adult mammalian NMJs)-related calcium influx dependence of the muscarinic effect (both M1 and M2) on ACh release that we describe here suggests that the presynaptic axonal membrane can locate the mAChRs involved in modulating transmitter release. Nevertheless, Schwann cells also have muscarinic and purinergic receptors which seem to regulate the genetic expression in these cells (Robitaille et al., 1997) .
We found that P/Q-type VDCC may be involved in both M1-and M2-mediated mechanisms of transmitter release modulation. The evoked ACh release from mature mammalian motor nerve terminals (MNTs) is mediated by the calcium influx through VDCCs of the P/Qtype (Uchitel et al., 1992; Protti & Uchitel, 1993; Bowersox et al., 1995; Hong & Chang, 1995) . In contrast, neither the L-type nor the Ntype VDCC participates in the evoked release of ACh in these mature MNTs (Penner & Dreyer, 1986; Atchison, 1989; Protti et al., 1991; Bowersox et al., 1995) . The contribution of N-type calcium channels to synaptic transmission seems quite general among synapses in developing animals (Iwasaki et al., 2000) but it remains only in a subset of synapses in mature animals. Some of this pharmacological evidence has been reinforced by immunocytochemical techniques (Day et al., 1997; Westenbroek et al., 1998) .
In frog NMJ, Slutsky et al. (1999) found that the M2-mediated inhibitory effect of muscarine on ACh release was not associated with a reduction in the Ca 2þ current, whereas the M1-mediated enhancement effect was associated with an increase in it. N-type channels can control the transmitter release in the frog NMJ (Kerr & Yoshikami, 1984) , so in amphibia the coupling of the mAChRs with VDCC is different from the coupling in mammals. Also, in many central neurons that express several types of calcium channels (T-, N-, P-, Q-, L-and Rtype; Margeta-Mitrovic et al., 1997; Williams et al., 1997) , only the N-and P/Q-types were involved in muscarinic receptor-mediated autoinhibition via M2 mAChRs (Allen, 1999 ). It appears therefore that different calcium channels (P/Q-and N-type) in different kinds of cholinergic presynaptic axons can be coupled to the M1-and M2-mediated muscarinic mechanisms of transmitter-release modulation.
mAChRs in the newborn rat LAL muscle
We observed several developmental differences between the M1 and M2 muscarinic mechanisms. In fact, we found in newborn rats an M1-mediated, pirenzepine-sensitive release-enhancing mechanism that was similar to the one in adult rats. However, in newborn rats there was also an M2-mediated methoctramine-sensitive mechanism that can operate as a release-enhancement tool and that is the same size as the M1 mechanism. In the first few postnatal days therefore both M1 and M2 receptors were related to ACh release enhancement because the quantal content was low whichever receptor type was blocked. However, upon maturation in the first few weeks postnatal, the M2 pathway shifted to perform the release-inhibitory activity described in the adult.
There are several explanations for the specific action of methoctramine in the newborn animal. As we found no M3 (4-DAMPsensitive) or M4 (tropicamide-sensitive) muscarinic receptors that produce complex cross-reactions, we cannot rule out the possibility that the mAChRs in the newborn rats are endowed with nonstandard properties such as a common sensitivity to different antagonists. Interestingly, and unlike in the adult rats, when methoctramine and pirenzepine were sequentially added, we observed that the reduction in ACh release produced by the first drug was not modified by the second drug. This suggests that there is a common intracellular pathway turned on by the two receptors. However, the different dependence of the two muscarinic mechanisms from the VDCC disputes this. The pirenzepine-sensitive mechanism does not depend on the P/Q-type calcium channel or the N-type calcium channel, whereas the methoctramine-sensitive mechanism can depend on the P/Q-type channel but not on the N-type channel. Although the N-type channel is present in the newborn NMJs and participates in the calcium-dependent release with the P/Q-type channel (Rosato-Siri & Uchitel, 1999 ; see also Santafé et al., 2001) , our present data indicate that the N-type channel is not coupled to M1-or M2-dependent ACh release automodulation.
Whatever the case, the final result may be the existence of a dual M1-M2 muscarinic mechanism in the newborn MNT that is intended to favour ACh release. While the MNT develops, the amount of transmitter release is small (Dennis et al., 1981 ) and there appears to be a need for simultaneous M1 and M2 muscarinic positive feedback. A similar requirement for multiple VDCC seems to affect the inflow of calcium during neuromuscular transmission in the newborn NMJ (as in many central neurons). Calcium may need to enter through more than one type of channel to trigger secretion (Mintz et al., 1995; Allen, 1999; Santafé et al., 2001) . We suggest that, because of this muscarinic autoreceptor configuration in the newborn, ACh in the synaptic cleft, which is mainly released by the endings where activity is higher (see Jansen & Fladby, 1990) , would directly potentiate the neurotransmission in these endings. This potentiation may be a significant factor in neonatal axonal competition and the activity-dependent developmentally regulated synapse elimination (Benoit & Changeux, 1975; O'Brien et al., 1978) .
At this stage we cannot offer a physiological implication for the developmental change in M2 receptor-mediated effects from release enhancing to release inhibiting. However, the feedback inhibition indicates the existence in the adult of an autoreceptor-mediated fine tuning that controls the exocytotic machinery of neurotransmitter release.
In summary, we demonstrate M1 and M2 receptors in both newborn and adult neuromuscular junctions. In the newborn rat there is an M1-mediated, pirenzepine-sensitive and VDCC-independent releaseenhancing mechanism that upon maturation can acquire P/Q-type VDCC dependence in the adult. There is also an M2-mediated methoctramine-sensitive and VDCC-dependent (P/Q-type) mechanism that operates to enhance release. However, upon maturation in the first few weeks postnatal, the M2 pathway shifts to perform the calcium-dependent release-inhibitory activity found in the adult. junction; VDCC, voltage-dependent calcium channels; Vm, membrane potential; o-Aga-IVA, o-Agatoxin-IVA; o-CgTX-GVIA, o-conotoxin-GVIA.
